Who are 4D Molecular Therapeutics, Inc.'s main suppliers?

4D Molecular Therapeutics, Inc. (FDMT) key suppliers include: REGENXBIO Inc., Sanofi, Sanofi. View the full supplier network at chainsifter.com/chain/FDMT.

Who are 4D Molecular Therapeutics, Inc.'s major customers?

4D Molecular Therapeutics, Inc. (FDMT) key customers include: REGENXBIO Inc., Sanofi, Sanofi. View the full customer network at chainsifter.com/chain/FDMT.

What sector is 4D Molecular Therapeutics, Inc. in?

4D Molecular Therapeutics, Inc. (FDMT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

FDMT Supply Chain: 4D Molecular Therapeutics, Inc. Supplier List & 9 Relationships

3Suppliers

3Customers

3Debt Items

20Related Chains

4D Molecular Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
RGNX	REGENXBIO Inc.	72%	Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
SNYNF	Sanofi	72%	val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from SNYN…

4D Molecular Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
RGNX	REGENXBIO Inc.	72%	Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
SNYNF	Sanofi	72%	val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain ti…

4D Molecular Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
FDMT-DEBT	Debt stack $20.5M	90%	Market cache reports total debt of $20.5M.
FDMT-DEBT-9461	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.
FDMT-DEBT-9460	Warrants outstanding: 45000	90%	xbrl warrant detail from xbrl 2025-12-31.

4D Molecular Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for 4D Molecular Therapeutics, Inc..

4D Molecular Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
FDMT-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 152 tracked holders.

4D Molecular Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
BIOA	BioAge Labs, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2

4D Molecular Therapeutics, Inc. Supply Chain